Cargando…
RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
Increased synthesis of Apolipoprotein A-I (ApoA-I) and HDL is believed to provide a new approach to treating atherosclerosis through the stimulation of reverse cholesterol transport. RVX-208 increases the production of ApoA-I in hepatocytes in vitro, and in vivo in monkeys and humans, which results...
Autores principales: | McLure, Kevin G., Gesner, Emily M., Tsujikawa, Laura, Kharenko, Olesya A., Attwell, Sarah, Campeau, Eric, Wasiak, Sylwia, Stein, Adam, White, Andre, Fontano, Eric, Suto, Robert K., Wong, Norman C. W., Wagner, Gregory S., Hansen, Henrik C., Young, Peter R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877016/ https://www.ncbi.nlm.nih.gov/pubmed/24391744 http://dx.doi.org/10.1371/journal.pone.0083190 |
Ejemplares similares
-
Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)
por: Wasiak, Sylwia, et al.
Publicado: (2017) -
RVX 208
Publicado: (2012) -
Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes
por: Wasiak, Sylwia, et al.
Publicado: (2016) -
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
por: Tsujikawa, Laura M., et al.
Publicado: (2019) -
BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency
por: Lu, Panpan, et al.
Publicado: (2017)